Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction

Weiss, Thomas W.; Aichinger, Josef; Huber, Kurt; Speidl, Walter S.; Watzinger, Norbert; Zweiker, Robert; Alber, Hannes

doi:10.1007/s00508-016-1016-7

Cited by 3 publications

(1 citation statement)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excess apoptosis of VECs is a preliminary event in thrombosis development [ 5 ]. In order to prevent platelet aggregation induced by the stent metal framework and thrombus formation that blocks blood vessels, patients receiving PCI must receive dual antithrombotic therapy [ 6 ]. However, dual antithrombotic treatment after stenting increases the risk of bleeding complications in patients [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Downregulation of TRPC4 and TRPC5 Inhibits Smooth Muscle Cell Proliferation without Affecting Endothelial Cell Proliferation

Zeng

Zhang

et al. 2021

Genetics Research

View full text Add to dashboard Cite

Aims. The main treatment for coronary heart disease is percutaneous coronary intervention (PCI), and drug-eluting stents are designed to inhibit vascular smooth muscle cell (VSMCs) proliferation and migration causing restenosis by releasing pharmacological agents into the vessel wall. Once drug-eluting stents are deployed, these pharmacological agents exert many biological effects in the coronary circulation, not only inhibition of VSMCs but also extension to vascular endothelial cells (VECs). The purpose of this study was to explore target molecules that inhibit VSMCs proliferation without affecting VECs. Methods. mRNA and protein expressions of transient receptor potential channels (TRPCs) in cultured VSMCs and VECs were determined by western blotting and RT-qPCR. VSMCs and VECs proliferation was evaluated using CCK-8 assays and western blotting of proliferating cell nuclear antigen (PCNA). Calcium backfilling assays were performed to detect intracellular calcium ion concentration in cultured VSMCs and VECs. Results. The TRPC6 expression was more abundant in VECs than VSMCs, while TRPC4 and TRPC5 expressions were more abundant in VSMCs than VECs. Knockdown of TRPC4 or TRPC5 alone had no remarkable inhibitory effect on VSMC proliferation. Synergistic knockdown of TRPC4 and TRPC5 inhibited the proliferation of VSMCs, declined the expression of the PCNA, and reduced the intracellular calcium ion concentration but not VECs. Conclusion. These data suggest that concurrent inhibition of TRPC4 and TRPC5 inhibits VSMCs proliferation without affecting VECs, thus providing novel targets for developing pharmacological agents for drug-eluting stents.

show abstract

Section: Introductionmentioning

confidence: 99%

Downregulation of TRPC4 and TRPC5 Inhibits Smooth Muscle Cell Proliferation without Affecting Endothelial Cell Proliferation

Zeng

Zhang

et al. 2021

Genetics Research

View full text Add to dashboard Cite

show abstract

Sekundärpräventive Antiplättchentherapie in der kardiologischen Rehabilitation

Wanitschek

Alber

2017

Wien Med Wochenschr

Self Cite

View full text Add to dashboard Cite

Secondary prevention with antiplatelet therapy in cardiac rehabilitationSummary The long-term increased cardiovascular risk of patients with an acute coronary syndrome (ACS) is a challenging and common clinical problem. Recent evidence demonstrated an ischemic benefit for a prolonged dual antiplatelet therapy beyond the initial 12 months at the cost of an increased bleeding risk. Individual, careful and repeated risk-

show abstract

Lights and shadows of long-term dual antiplatelet therapy in “real life” clinical scenarios

Scherillo

Cirillo

Formigli

et al. 2018

J Thromb Thrombolysis

View full text Add to dashboard Cite

Dual antiplatelet therapy (DAPT) is a cornerstone of treatment for patients with acute coronary syndromes (ACS). Mounting evidences have opened the debate about the optimal DAPT duration. Considering the ACS-pathophysiology, the most recent guidelines recommend DAPT in all ACS patients for at least 12 months unless there are contraindications such as excessive risk of bleeding. Thus, it can be considered acceptable earlier discontinuation if the risk of morbidity from bleeding outweighs the anticipated benefit. On the other hand, several studies have clearly indicated that a significant burden of platelet related-events, such as stroke and new ACS might occur after this period, suggesting that potential benefits might derive by prolonging DAPT beyond 12 months (Long DAPT). Indeed, although current guidelines give some indications about patients eligible for Long DAPT, they do not embrace several real-life clinical scenarios. Thus, in such scenarios, how to decide whether a patient is eligible for Long DAPT or not might be still challenging for clinicians. This position paper presents and discusses various "real-life" clinical scenarios in ACS patients, in order to propose several possible recommendations to overcome guidelines potential limitations.

show abstract

Expert position paper on prolonged dual antiplatelet therapy in secondary prevention following myocardial infarction

Cited by 3 publications

References 26 publications

Downregulation of TRPC4 and TRPC5 Inhibits Smooth Muscle Cell Proliferation without Affecting Endothelial Cell Proliferation

Downregulation of TRPC4 and TRPC5 Inhibits Smooth Muscle Cell Proliferation without Affecting Endothelial Cell Proliferation

Sekundärpräventive Antiplättchentherapie in der kardiologischen Rehabilitation

Lights and shadows of long-term dual antiplatelet therapy in “real life” clinical scenarios

Contact Info

Product

Resources

About